Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds


We are thankful to our funding agencies for their support:

Baden Württemberg Stiftung


REsolvInG ImmuNITy to targEt Brain Tumors (RE-IGNITE). 2020 - 2023

Deutsche Krebshilfe


A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas – (INTERCEPT H3). 2019 - 2023

Microglial immune surveillance of oncogenic IDH (CONVINCE-IDH). 2022 - 2024



Deutsches Konsortium für Translationale Krebsforschung

TCR Proof of Concept in cooperation with NCT (TCR-POC)

AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial (AMPLIFY-NEOVAC, NOA-21)

CAR2Brain_Immune Response CAR-NK Immunotherapy in Glioblastoma_DKTK Joint Funding “UPGRADE”. 2020 - 2024

Insights into mechanisms of T cell response and resistance in post-treatment multicellular AMPLIFY NEOVAC glioma organoids (AMI2GO) 2021 - 2024

Intraventricular TCR therapy for glioblastoma (INVENT4GB) 2023 - 2026 

Deutsche Forschungsgemeinschaft - CRC 1366


Vascular control of tumor immunity in the CNS. CRC1366. 2019 - 2022

Deutsche Forschungsgemeinschaft - CRC UNITE 1389


Understanding and targeting resistance in glioblastoma. CRC UNITE 1389. 2019 - 2023


Deutsche Forschungsgemeinschaft - RTG 2099


Hallmarks of Skin Cancer, Tumor Microenvironment and Melanoma Immunity, Response and Resistance to Checkpoint Blockade in melanoma brain metastases. CRC RTG2099. 2019 - 2024

Deutsche Forschungsgemeinschaft - GRK 2727/1


InCheck „Innate Immune Checkpoints in Cancer and Tissue Damage" 



The role of CXCL10 in the immune regulation of melanoma and glioma. 2019 - 2022

Hertie Stiftung


Hertie Academy of clinical neuroscience als Kristallisationspunkt für ein Hertie Network of Excellence in clinical neuriscience. 2019 - 2022

Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control (UICC)


Swiss Bridge Award 2019 - T cell receptor transgenic cellular therapies targeting shared T helper cell neoepitopes in brain tumors. 2019 - 2022

Funding by the European Union


to top
powered by webEdition CMS